Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

RXi Pharmaceuticals to Present at the 25th Annual ROTH Conference

RXi Pharmaceuticals Corporation
Posted on: 12 Mar 13

RXi Pharmaceuticals Corporation (OTC: RXII) a biotechnology company focused on discovering developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies today announced that the Company’s President and Chief Executive Officer Dr. Geert Cauwenbergh will present at the 25th Annual ROTH Conference on Tuesday March 19th at 1:30pm PT. Dr. Cauwenbergh will discuss the development of RXI-109 a self-delivering RNAi compound designed to reduce dermal scarring as well as business development opportunities with RXi’s sd-rxRNA® technology platform.

A live webcast of the presentation will be available on the “Investors” section of the Company's website A replay of the presentation will be available 90 days.

This conference is being held March 17-20 2013 at the Ritz-Carlton Laguna Niguel in Dana Point CA. For more information visit:

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering developing and commercializing innovative therapies based on its proprietary self-delivering RNAi platform. Therapeutics that use RNA interference or “RNAi” have great promise because of their ability to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello a member of the RXi Scientific Advisory Board RXi’s first RNAi product candidate RXI-109 which targets CTGF entered into human clinical development in June 2012. For more information please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements about future expectations planned and future development of RXi Pharmaceuticals Corporation’s products and technologies. Forward-looking statements about expectations and development plans of RXi’s products involve significant risks and uncertainties: risks that RXi may not be able to successfully develop its candidates or that development of RNAi-based therapeutics may be delayed or not proceed as planned or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed risks related to development and commercialization of products by our competitors risks related to our ability to control timing and terms of collaborations with third parties and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views events or circumstances that occur after the date of this release.

Business Wire

Last updated on: 12/03/2013

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.